Pulses are our e-newsletters that look at recent trends and promising directions across life sciences. Add your name to our mail list to receive future updates.
CNS Pulse | July 2024
Rare neurodegenerative diseases have benefited from an influx of novel therapies, but the remaining unmet needs and clinical development strategies vary by disease and continue to pose a challenge.
Oncology Pulse | May 2024
Antibody-drug conjugates (ADCs) and radiopharmaceuticals have re-emerged as modalities of high interest in oncology licensing and acquisition – will they be the next wave of breakthroughs or represent a flight to safety in light of the challenges of finding the next hot target and the IRA?
Oncology Pulse | Jan. 2024
Follow-on targeted therapies and T-cell engagers for liquid tumors accounted for most of the new oncology agents last year; 18 drugs and 9 MOAs are already filed for this year, with cell therapies and a T-cell engager for solid tumors and a new ADC target on the list of potential approvals.
Gene Therapy Pulse | Dec. 2023
The cell and gene therapy space has seen significant growth in the last five years and continues to rapidly evolve. Realization of future potential faces key technical, clinical, and commerical challenges.
Oncology Pulse | Nov. 2023
For now, auto CAR-T is prioritized over bispecifics due to longer term data, but both approaches are seeking to push into earlier lines and allogeneic CAR-Ts are aiming to provide the efficacy of CAR-T with an off-the-shelf product.
Oncology Pulse | Sept. 2023
Segmenting PD-(L)1 rechallenge patients by type of resistance could be a path to success — and assumptions for efficacy post-CPI may need to be increased.
Oncology Pulse | May 2023
Targeted therapies have accounted for the majority of new oncology drugs over the past five years, but a more diverse set of approaches are being approved; IRA and accelerated approval changes also portend changes.